17,261 trials
Basal Cell Carcinoma
Primary: Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell…
Constipation
Primary: the Change in Mean Weekly CSBMs During Weeks 1-8 Since Treatment — 1.72; 0.82 number of times — p=<0.001
Psoriasis
Primary: Mean Gross Change in Psoriasis Area and Severity Index (PASI) Scores From Baseline to the End of 6 Months — -2.15; -1.69 units on a scale
Hypertension
Primary: 24-hour Urinary Sodium Excretion — 220.58; 198.73; 177.40; 146.18 mmol/24 hours
Stroke
Primary: Balance - Measured With the Berg Balance Scale — 46.3; 43.8 units on a scale
Glioblastoma Multiforme
Primary: Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months — 79.31; 42.59 percentage of participants — p=<0.0001
Colon Cancer · Rectal Cancer
Primary: To Determine Overall Objective Response. — 9; 6 participants
Non Small Cell Lung Cancer · Lung Cancer
Primary: Number of Patients With Pathologic Complete Response Rate — 1; 1; 2; 2 participants
Breast Cancer
Primary: Overall Response Rate — 20 participants
Neuroendocrine Tumors · Metastatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 13; 12 participants
Sarcoma · Synovial Sarcoma · Leiomyosarcoma
Primary: Overall Objective Response — 5; 22; 8 participants
Reduction of Hypertrophic Skin Scarring
Primary: Physician Global Assessment Using Physician Overall Opinion Question of Patient and Observer Scar Assessment Scale (POSAS) — 4.00; 4.68; 4.61; 4.86 units on scale…
Diabetes · Diabetes Mellitus, Type 2
Primary: Rate of Major and Minor Hypoglycaemic Episodes — 0; 0; 13.63; 21.83 Episodes /year of patient exposure
CLL
Primary: IwCLL-WG Defined Complete Response (CR) — 1 participants
Breast Cancer · Lung Cancer · Prostate Cancer
Primary: Determine Response Rate of Patients > or = to 65 Yrs Diagnosed — 63; 24 participants